Authors
Latest:
Dr Adige on Improving QOL Post–Breast Cancer TreatmentSunil Adige, MD, discusses aspects of post-treatment care that can improve long-term quality of life and reduce the risk of breast cancer recurrence.
Latest:
Dr Yilmaz on HB-200 Arenavirus Plus Pembrolizumab in HPV16+ Head and Neck CancerEmrullah Yilmaz, MD, PhD, discusses HB-200 arenavirus–based immunotherapy plus pembrolizumab in recurrent/metastatic HPV16+ head and neck cancer.
Latest:
Emily Skotte, MSN on Rash Management in Patients Treated With EGFR TKIsEmily Skotte, MSN, discusses common ways to manage the rashes that may occur as adverse effects in patients treated with EGFR TKIs.
Latest:
Dr Smith on Next Steps With the KELIM Score and HIPEC in Epithelial Ovarian CancerGabriella Smith, MD, discusses the predictive value of KELIM for survival outcomes with HIPEC at the time of surgery in epithelial ovarian cancer.
Latest:
Dr Tremblay on the Identification and Prevalence of MDS/MPN Overlap SyndromesDouglas A. Tremblay, MD, discusses the prevalence of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and the evolving treatment paradigm for these diseases.
Latest:
Dr. Ghali on Nectin-4 and TROP-2 Expression in Urothelial, Variant Histology Bladder CancerFady Ghali, MD, discusses the expression of Nectin-4 and TROP-2 in variant histology bladder cancer and urothelial cancer.
Latest:
Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral CentersPanelists discuss how community providers can implement strategies and utilize resources to effectively connect patients to referral centers for chimeric antigen receptor T-cell therapy, while addressing how to initiate conversations about the therapy and counsel patients regarding potential adverse events.
Latest:
Dr. Hwu on the Uptake of Cellular Therapy in OncologyPatrick Hwu, MD, discusses the uptake of cellular therapy in the treatment of patients with cancer.
Latest:
Dr Reichert on Key Research Questions in Prostate CancerZachery Roger Reichert, MD, PhD, discusses key research questions to explore in early-stage prostate cancer.
Latest:
Dr Koo on Challenges With PSMA PET in Prostate CancerPhillip J. Koo, MD, discusses the utility of next-generation imaging in prostate cancer, highlighting the use of PSMA PET in this patient population.
Latest:
Current Standard of Care for Locally Advanced or Metastatic Cutaneous Squamous Cell CarcinomaNikhil I. Khushalani, MD, of Moffitt Cancer Center, discusses current therapeutic options for patients with locally advanced cutaneous squamous cell carcinoma.
Latest:
Dr Christenson on the Safety of Copanlisib Plus Nivolumab in Pretreated MSS mCRCEric S. Christenson, MD, discusses the safety of copanlisib plus nivolumab in pretreated, PIK3Ca-mutated microsatellite stable, unresectable or metastatic colorectal cancer.
Latest:
Small Cell Lung Cancer: What is the Role of IO Therapy in the Frontline Setting?A brief review of the role that immunotherapy agents play in the frontline management of patients with small cell lung cancer.
Latest:
Dr Di Federico on an Analysis of TTF-1 Expression in Lung AdenocarcinomaAlessandro Di Federico, MD, discusses findings from a study investigating the correlation between TTF-1 expression and outcomes with immunotherapy-based treatments in patients with lung adenocarcinoma.
Latest:
Dr Seetharamu on Current Platforms Utilized for Molecular Testing in Lung CancerNagashree Seetharamu, MD, MBBS, discusses currently utilized platforms and workflows for molecular testing in lung cancer at Northwell Health.
Latest:
Dr Badar on Outcomes With Imetelstat in Lower-Risk MDSTalha Badar, MBBS, MD, discusses key efficacy data with imetelstat from the phase 2/3 IMerge trial of patients with lower-risk myelodysplastic syndrome.
Latest:
Dr Spiegel on the Challenges Associated With CAR T-Cell Therapy in Solid TumorsJay Spiegel, MD, discusses some of the challenges of using CAR T-cell therapy in patients with solid tumors.
Latest:
Dr. Davis on the Influence of Racial Constructs and Genetic Ancestry in TNBCMelissa B. Davis, PhD, discusses the influence of racial constructs and genetic ancestry in triple negative breast cancer.
Latest:
Dr Fisher on Mechanisms of Resistance to Pirtobrutinib in CLLDavid C. Fisher, MD, discusses pirtobrutinib resistance mechanisms that may develop during therapy in patients with CLL
Latest:
Dr Devoe on Next Steps for Evaluating ELI-002 7P in MRD+ KRAS-Mutant PDAC and CRCCraig E. Devoe, MD, MS, discusses next steps for assessing the ELI-002 7P vaccine in patients with MRD–positive, KRAS-mutant PDAC and CRC.
Latest:
Dr Saltos on Pembrolizumab Plus Vorinostat in mNSCLCAndreas Saltos, MD, discusses final results from a phase 2 trial of first-line pembrolizumab plus vorinostat in patients with metastatic non–small cell lung cancer.
Latest:
Dr Arianna Gianakos: Innovation and Trailblazing Paths in OrthobiologicsArianna Gianakos, DO, discusses the innovation in orthobiologics and trailblazing paths in equity and advocacy.
Latest:
Building Upon ScaffoldsCancer care is changing rapidly, and understanding and incorporating new practices is challenging both for practicing oncologists and oncology trainees.
Latest:
Moffitt Study Links Methylmalonic Acid to Weakening of Immune Cells in Lung CancerA new study has found a surprising link between high levels of methylmalonic acid and the weakening of CD8+ T cells, shedding light on potential pathways through which aging may promote lung cancer progression.
Latest:
Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPCDrs Manning and Armstrong discuss the impact of lesion size and symptomatic status of bone metastases on radiotherapy selection in mCRPC, highlighting ongoing trials and emerging data.
Latest:
Dr Krishnamurthy on Treatment Sequencing Based on Mutation Status in HR+/HER2– Breast CancerJairam Krishnamurthy, MD, FACP, discusses the use of mutation status to inform treatment sequencing in HR-positive, HER2-negative metastatic breast cancer.
Latest:
Dr. Buske on the Results of the iNNOVATE Trial in Waldenström MacroglobulinemiaChristian Buske, MD, discusses the results of the iNNOVATE trial in Waldenström macroglobulinemia.
.jpg?fit=crop&auto=format)
